Short communicationStudy of in vitro metabolism of M-NISOLDIPINE (cas 113578-26-0) in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography–mass spectrometry
-
Add time:08/22/2019 Source:sciencedirect.com
This is a report about the investigation of the metabolic fate of M-NISOLDIPINE (cas 113578-26-0) in human liver microsomes and the recombinant cytochrome P450 enzymes by using LC–MS/MS. A sensitive and reliable LC–MS/MS method was developed to obtain a rapid and complete characterization of new metabolites and the metabolism pathways. The analytes were separated on a reversed phase C18 column with acetonitrile and 0.1% aqueous formic acid as the mobile phase. Tandem mass spectrometry with positive electrospray ionization was used to enable the structural characterization of the metabolites. A total of 10 metabolites were characterized with proposed structures in the incubation of human liver microsomes by comparing their retention times and spectral patterns with those of the parent drug. Dehydrogenation of the dihydropyridine core and reactions of side chains such as hydroxylation and hydrolysis of ester bonds were the major metabolic pathways. The specific cytochrome P450 (CYP) enzymes responsible for m-nisoldipine metabolites were identified using chemical inhibition and cDNA expressed CYP enzymes. The results indicated that CYP2C19 and CYP3A4 might play major roles in the metabolism of m-nisoldipine in human liver microsomes.
We also recommend Trading Suppliers and Manufacturers of M-NISOLDIPINE (cas 113578-26-0). Pls Click Website Link as below: cas 113578-26-0 suppliers
Prev:Short communicationStudies on separation and pharmacokinetics of M-NISOLDIPINE (cas 113578-26-0) enantiomers in beagle dog plasma by LC/MS/MS
Next:Thermodynamic stability analysis of M-NISOLDIPINE (cas 113578-26-0) polymorphs) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ContributionsAntihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension08/29/2019
- Cyclic voltammetric behaviour of the O2/O2− redox couple at a HMDE and its interaction with nisoldipine08/28/2019
- Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic−mass spectrometry: applications to pharmacokinetics08/27/2019
- Validated LC–MS–MS method for determination of M-NISOLDIPINE (cas 113578-26-0) polymorphs in rat plasma and its application to pharmacokinetic studies08/26/2019
- Molecular and Cellular PharmacologyThe inhibitory effects of M-NISOLDIPINE (cas 113578-26-0) on the 5-hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells via Ca2+ antagonism and antioxidant mechanisms08/25/2019
- Simultaneous determination of M-NISOLDIPINE (cas 113578-26-0) and its three metabolites in rat plasma by liquid chromatography–mass spectrometry08/24/2019
- Thermodynamic stability analysis of M-NISOLDIPINE (cas 113578-26-0) polymorphs08/23/2019
- Short communicationStudies on separation and pharmacokinetics of M-NISOLDIPINE (cas 113578-26-0) enantiomers in beagle dog plasma by LC/MS/MS08/21/2019
- Original articleOn the dimorphism and the pressure–temperature state diagram of racemic M-NISOLDIPINE (cas 113578-26-0), a dihydropyridine calcium ion antagonistSur le dimorphisme et le diagramme d’état pression-température de la M-NISOLDIPINE (cas 113578-26-0) racémique, une dihydroyridine antagoniste08/20/2019


